Free Trial

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

-0.81 (-1.83%)
(As of 10:14 AM ET)
Today's Range
50-Day Range
52-Week Range
81,674 shs
Average Volume
1.05 million shs
Market Capitalization
$3.22 billion
P/E Ratio
Dividend Yield
Price Target

SpringWorks Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
55.5% Upside
$68.83 Price Target
Short Interest
13.51% of Shares Sold Short
Dividend Strength
News Sentiment
0.95mentions of SpringWorks Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($4.60) to ($3.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

617th out of 920 stocks

Biological Products, Except Diagnostic Industry

91st out of 153 stocks

SWTX stock logo

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Stock Price History

SWTX Stock News Headlines

SpringWorks Therapeutics: Q1 Earnings Snapshot
SWTX Quantitative Stock Analysis
SWTX Apr 2024 70.000 call
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
SWTX Apr 2024 60.000 put
SWTX Apr 2024 65.000 call
See More Headlines
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$5.45 million
Book Value
$7.66 per share


Free Float
Market Cap
$3.20 billion

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Francis I. Perier Jr. (Age 64)
    M.B.A., Chief Financial Officer
    Comp: $768.24k
  • Dr. Badreddin Edris Ph.D. (Age 37)
    Chief Operating Officer
    Comp: $1.02M
  • Dr. James Cassidy M.D. (Age 64)
    Ph.D., Chief Medical Officer
    Comp: $904.25k
  • Mr. Michael P. Nofi (Age 53)
    Chief Accounting Officer
  • Mr. Tai-An Lin Ph.D.
    Chief Scientific Officer
  • Ms. Kim Diamond
    Vice President of Communications & Investor Relations
  • Mr. Herschel S. Weinstein J.D. (Age 67)
    General Counsel & Secretary
    Comp: $568.64k
  • Mr. Daniel J. PichlMr. Daniel J. Pichl (Age 40)
    Chief People Officer
    Comp: $428.51k
  • Mr. Bhavesh Ashar M.B.A. (Age 58)
    Chief Commercial Officer
    Comp: $729.62k

SWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings
or view top-rated stocks.

What is SpringWorks Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1 year price objectives for SpringWorks Therapeutics' shares. Their SWTX share price targets range from $52.00 to $75.00. On average, they anticipate the company's share price to reach $68.83 in the next twelve months. This suggests a possible upside of 55.5% from the stock's current price.
View analysts price targets for SWTX
or view top-rated stocks among Wall Street analysts.

How have SWTX shares performed in 2024?

SpringWorks Therapeutics' stock was trading at $36.50 on January 1st, 2024. Since then, SWTX shares have increased by 21.3% and is now trading at $44.27.
View the best growth stocks for 2024 here

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our SWTX earnings forecast

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) posted its quarterly earnings data on Thursday, May, 2nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.17) by $0.01. The company had revenue of $21 million for the quarter, compared to the consensus estimate of $12.07 million. SpringWorks Therapeutics's revenue for the quarter was up 2000.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.18) earnings per share.

What other stocks do shareholders of SpringWorks Therapeutics own?
When did SpringWorks Therapeutics IPO?

SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.81%), Price T Rowe Associates Inc. MD (5.55%), Lord Abbett & CO. LLC (3.13%), Artal Group S.A. (1.91%), Jane Street Group LLC (0.78%) and Bessemer Group Inc. (0.25%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc and Saqib Islam.
View institutional ownership trends

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does SpringWorks Therapeutics have any subsidiaries?
The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More
This page (NASDAQ:SWTX) was last updated on 5/23/2024 by Staff

From Our Partners